A phase 1b trial of IRL 757 for the treatment of Parkinson's disease and apathy
Latest Information Update: 02 Jun 2025
At a glance
- Drugs IRL-757 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
Most Recent Events
- 02 Jun 2025 New trial record
- 28 May 2025 Accroding to an IRLAB Therapeutics media release, Based on the positive results from the completed Phase I studies, a clinical Phase Ib study in Parkinsons disease and apathy has been initiated in cooperation with The McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. The first patients are expected to be enrolled in the study in the second half of 2025.